A novel topical ophthalmic formulation of the preferential COX-2 inhibitor meloxicam has recently been developed. The purpose of the present study was to evaluate the efficacy and safety of this novel 0.03% meloxicam solution with regard to a reference 0.1% diclofenac formulation in a prospective, parallel, randomized, multicenter, double-blind study. Two groups of patients submitted to phacoem...

A simple, accurate, precise, reproducible RP-HPLC method has been developed for simultaneous estimation of meloxicam and paracetamol with its genotoxic impurity (p-amino phenol) in bulk and combined dosage form (tablet). The method was validated in compliance with ICH guidelines[1-2]. The LC separation was achieved on Lichrospher RP-18e (250X4.6mm), 5μm column at 285 nm in isocratic mode using ...

OBJECTIVE This study aimed to quantify the cartilage- and subchondral bone-related effects of low-dose and high-dose meloxicam treatment in the late phase of mono-iodoacetate-induced osteoarthritis of the stifle. METHODS Thirty-four male Wistar rats received intra-articular injection of mono-iodoacetate to trigger osteoarthritis; 10 control animals (Grp Co) received saline. The mono-iodoaceta...

Acute rhabdomyolysis is a clinical and laboratory syndrome resulting from the breakdown of skeletal muscle, with the release of intracellular contents into the circulatory system, which can cause potentially lethal complications. Here, we present the case of a patient who developed acute rhabdomyolysis after consumption of meloxicam for jaw pain and experienced generalized myalgias in the conte...

Background: Non-steroidal anti-inflammatory drugs (NSAID) have been associated with antioxidant property and have been shown to improve the circulating antioxidant status on daily dosing in different inflammatory conditions. The present study was conducted to investigate the antioxidant role of meloxicam in aluminum induced oxidative stress in rat brain. Methods: In the in vivo experiments, Spr...

The purpose of this study was to determine the acid dissociation constants (pKa) of meloxicam in the presence of various surfactants including sodium lauryl sulfate (SLS) as an anionic surfactant, cetyltrimethylammonium bromide (CTAB) as a cationic surfactant and Triton® TX-100 (TX-100) as a non-ionic surfactant in different pre-determined concentrations. The related pKa was determined spec...

AIM Cholestasis triggers fibrogenesis in the liver. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic liver diseases caused either by viruses or toxins. We hypothesized that selective COX-2 inhibitor meloxicam could suppress inflammation and fibrogenesis in a rat model of cholestasis induced by bile duct ligation (BDL). METHODS Forty-three Sprague-Dawley rats were assig...

Meloxicam, a non-steroidal anti-Inflammatory drug (NSAID), has been reported as a safe substitute for diclofenac which was banned for veterinary use during 2005-06, due to its relay toxicity associated with the catastrophic decline in vulture populations in Indian subcontinent. It is a preferential cyclooxygenase-2 (COX-2) inhibiter with higher therapeutic index as compared to diclofenac, indom...

AIM To determine the efficacy of meloxicam ophthalmic formulation on COX-2 activity and expression, inflammation-related cytokines expression and inflammation in an ocular inflammation model. METHODS Ocular inflammation was induced in New Zealand rabbits by topical application of croton oil (3%) for 3 h. An ophthalmic solution of 0.03% meloxicam, 0.1% sodium diclofenac or vehicle (Sophisen) w...